The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
Comparison Chart: SGLT2 Inhibitors (online only)
Download PDF:   US English
Med Lett Drugs Ther. 2020 Nov 16;62(1611):e184-8
Disclosures
Principal Faculty
  • Mark Abramowicz, M.D., President: no disclosure or potential conflict of interest to report
  • Jean-Marie Pflomm, Pharm.D., Editor in Chief: no disclosure or potential conflict of interest to report
  • Brinda M. Shah, Pharm.D., Consulting Editor: no disclosure or potential conflict of interest to report
  • F. Peter Swanson, M.D., Consulting Editor: no disclosure or potential conflict of interest to report
Objective(s)
Upon completion of this activity, the participant will be able to:
  1. Review the efficacy of empagliflozin (Jardiance) in patients with heart failure
 Select a term to see related articles  canagliflozin   dapagliflozin   empagliflozin   ertugliflozin   Farxiga   Forxiga   Glyxambi   Invokamet   Invokana   Jardiance   linagliptin   Metformin   Qtern   Saxagliptin   Segluromet   sitagliptin   Steglatro   Steglujan   Synjardy   Xigduo 
Updated May 17, 2021

View the Comparison Chart: SGLT2 Inhibitors
Download PDF: US English

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article